Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/3381/9/20: Boehringer Ingelheim – Trajenta digital banner ad (no breach)

Complaint about Trajenta online banner claims (β€œbroad range”, β€œunique convenience”) and legibility of prescribing info link. Panel found…

8 Mar 2026

AUTH/3520/6/21: NHS commissioning manager v Sanofi (flu vaccine promotion/availability) – No breach

Complaint about Sanofi’s flu vaccine ordering communications and a 30% QIVe dose reduction (with QIVr as an alternative).…

8 Mar 2026

Stallergenes Greer: LinkedIn post naming POM brands ruled promotion to the public (AUTH/3570/10/21)

A corporate LinkedIn post named brands and an indication for a newly authorised SLIT tablet. PMCPA ruled this…

8 Mar 2026

Novartis breached Code over Kesimpta SMC β€œapproval” stamp and UK digital ad (missing β€˜adult’ + NI prescribing info) (AUTH/3643/5/22)

Kesimpta promo webpage implied unrestricted SMC approval (restriction not in immediate view). A UK HCP banner ad omitted…

8 Mar 2026

AUTH/3759/4/23: Boehringer Ingelheim clinical trial recruitment flyer at BSG Conference 2023 – No breach

Anonymous complaint alleged a Phase 2/3 sarcoma trial flyer in conference bags was pre-licence promotion and inappropriately distributed.…

8 Mar 2026

AUTH/3790/7/23: Ex-employee v Moderna (preprint data in presentations) β€” No breach

Anonymous ex-employee alleged Moderna misused preprint vaccine effectiveness data, cherry-picked graphs and sought UK contract advantage via JCVI…

8 Mar 2026

Eli Lilly: Sponsored breast cancer editorial promoted via Facebook/Instagram ads reached the public (Clause 26) and lacked clear sponsorship at the outset

A medical publisher’s β€œSponsored” Facebook ad linked to a Lilly-funded breast cancer article. The Panel found disguised promotion,…

8 Mar 2026

AUTH/2131/6/08: Community pharmacist v GrΓΌnenthal Ltd – promotion of Versatis and use of interim comparative data

A pharmacist challenged claims that Versatis was comparable to pregabalin (and possibly gabapentin) and had fewer side-effects/interactions. The…

8 Mar 2026

GSK and Roche: Bonviva β€˜Building Bones’ ad reappeared in Pulse, breaching an undertaking (AUTH/2049/9/07 & AUTH/2050/9/07)

GSK and Roche withdrew Bonviva β€˜Building Bones’ materials after an undertaking, but Pulse republished the old ad. Panel…

8 Mar 2026

Flynn Pharma: Actiq β€œturn it on… and off” strapline ruled misleading (AUTH/2303/3/10)

Actiq ad and leavepiece implied breakthrough cancer pain control could be switched β€œon” and β€œoff” like an appliance.…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training